YAP1 and cancer: This general resistance mechanism to multiple KRAS inhibitors sheds light on an opportunity to overcome resistance to KRAS inhibitors and improve outcomes for patients with KRAS-mutant cancers through modulation of the Hippo-YAP/TAZ pathway.